In the third quarter, Acuitas Investments LLC reduced its position in MarineMax by 81.1%, selling 85,384 shares and retaining just 19,897 shares. Following the sale, Acuitas’s remaining stake represented approximately 0.09% of the company’s outstanding shares, valued at about $504,000 in its latest Securities and Exchange Commission filing. This significant divestiture marks one of the largest single-quarter reductions by a major institutional holder in MarineMax this fiscal year.

Several other large investors adjusted their positions in MarineMax during recent reporting periods. Levin Capital Strategies L.P. increased its holding by 44.5%, acquiring an additional 225,992 shares to reach a total of 734,279 shares. Private Management Group Inc. lifted its stake by 4.3%, adding 24,124 shares for a cumulative 583,220‐share position. New entrants during the second and third quarters included Campbell & Co. Investment Adviser LLC, Permanent Capital Management LP, and Corient Private Wealth LLC, deploying between $392,000 and $2.8 million into initial positions. As of the most recent filings, institutional investors collectively control 92.85% of MarineMax.

MarineMax reported first-quarter fiscal 2026 revenue of $505.2 million, up 7.8% year-over-year, driven by over 10% same‐store sales growth. Gross profit margin contracted to 31.8% from 36.2% a year earlier, reflecting continued promotional pressure and industry inventory normalization. The quarter produced a net loss of $7.9 million (a $0.36 per share loss), versus a net income of $18.1 million ($0.77 per share) in the prior‐year period. Adjusted EBITDA totaled $15.5 million, below the prior year’s $26.1 million, while inventories declined by $167.3 million from the previous year’s quarter end.

Wall Street research firms maintain a cautiously positive stance on MarineMax. Four analysts currently recommend a purchase, one holds, and one advises a sell, yielding an average consensus rating of “Moderate Buy.” Recent revisions include an upgrade from sell to hold by Zacks Research and a price objective increase to $29.00 by Truist Financial, following a reiteration of buy ratings from Citigroup and other firms. Analysts project full-year earnings per share of approximately 2.41, reflecting expectations for margin recovery and continued sales momentum through the spring selling season.